ADCs  are used as anti-HER2 therapies. ADCs can target the HER2 protein on cancer cells and deliver a cytotoxic drug to kill them. There are currently several anti-HER2 ADCs approved for the treatment of HER2-positive breast cancer, including T-DM1 and trastuzumab deruxtecan.